Henoch-schonlein purpura and drugs of ingredients of ceftriaxone sodium - a phase IV clinical study of FDA data


Summary:

Henoch-schonlein purpura is found among people who take drugs with ingredients of ceftriaxone sodium, especially for people who are male, 60+ old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 48,296 people who have side effects when taking drugs with ingredients of ceftriaxone sodium from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Ceftriaxone, Ceftriaxone and dextrose in duplex container, Ceftriaxone in plastic container, Ceftriaxone sodium, Rocephin, Rocephin w/ dextrose in plastic container.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Feb, 07, 2023

48,296 people reported to have side effects when taking drugs with ingredients of ceftriaxone sodium.
Among them, 108 people (0.22%) have Henoch-schonlein purpura


What is Henoch-schonlein purpura?

Henoch-schonlein purpura (inflammation of the blood vessels in the skin and other body organs) is found to be associated with 994 drugs and 772 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of ceftriaxone sodium cause Henoch-schonlein purpura?

Time on drugs with ingredients of ceftriaxone sodium when people have Henoch-schonlein purpura *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Henoch-schonlein purpura when taking drugs with ingredients of ceftriaxone sodium *:

  • female: 42.86 %
  • male: 57.14 %

Age of people who have Henoch-schonlein purpura when taking drugs with ingredients of ceftriaxone sodium *:

  • 0-1: 0.0 %
  • 2-9: 3.96 %
  • 10-19: 0.99 %
  • 20-29: 5.94 %
  • 30-39: 1.98 %
  • 40-49: 7.92 %
  • 50-59: 10.89 %
  • 60+: 68.32 %

Conditions people have *:

  1. Stress And Anxiety: 10 people, 9.26%
  2. Kidney Infection (Pyelonephritis): 9 people, 8.33%
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 5 people, 4.63%
  4. Haematoma (collection of blood outside the blood vessels): 5 people, 4.63%
  5. Herpes Dermatitis (skin inflammation caused by a herpes simplex virus (hsv)): 4 people, 3.70%
  6. Staphylococcal Bacteraemia (a bacterial infection of blood): 4 people, 3.70%
  7. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 3.70%
  8. Osteitis (a general term for inflammation of bone): 3 people, 2.78%
  9. Pain: 3 people, 2.78%
  10. High Blood Pressure: 3 people, 2.78%

Other drugs people take *:

  1. Nexium: 15 people, 13.89%
  2. Vancomycin: 14 people, 12.96%
  3. Lovenox: 10 people, 9.26%
  4. Calciparine: 9 people, 8.33%
  5. Bactrim Ds: 8 people, 7.41%
  6. Flagyl: 8 people, 7.41%
  7. Cordarone: 8 people, 7.41%
  8. Xanax: 8 people, 7.41%
  9. Gentamicin: 8 people, 7.41%
  10. Atarax: 8 people, 7.41%

Other side effects people have besides Henoch-schonlein purpura *:

  1. Joint Pain: 16 people, 14.81%
  2. Rashes (redness): 12 people, 11.11%
  3. Haematuria (presence of blood in urine): 9 people, 8.33%
  4. Leukocytoclastic Vasculitis (inflammation of small blood vessels (usually post-capillary venules in the dermis), characterized by palpable purpura): 8 people, 7.41%
  5. Abdominal Pain: 7 people, 6.48%
  6. Weakness: 6 people, 5.56%
  7. Cutaneous Vasculitis (an inflammatory process affecting the vessel wall that leads to its damage): 6 people, 5.56%
  8. Acute Kidney Failure: 6 people, 5.56%
  9. Itching: 6 people, 5.56%
  10. Renal Impairment (severely reduced kidney function): 6 people, 5.56%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Drugs with ingredients of ceftriaxone sodium, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: